Pfizer competitorsClear all

Pfizer's top competitors include Abbott, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Amgen, Takeda Pharmaceutical, Roche and Bayer.
Pfizer
Pfizer
Pfizer is a research-based biopharmaceutical company developing and manufacturing human and veterinary medicines, as well as consumer healthcare products.
Abbott
Abbott
Abbott is a healthcare company specializing in diagnostics, medical devices, nutritionals, and branded generic medicines.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases.
Eli Lilly
Eli Lilly
Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of products in the pharmaceutical business segment.
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline is a science-led healthcare company.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Merck
Merck
Merck is a healthcare manufacturer and distributor of pharmaceuticals.
Novartis
Novartis
Novartis is a company that researches, develops, manufactures, and markets a range of healthcare products.
Amgen
Amgen
Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products.
Takeda Pharmaceutical
Takeda Pharmaceutical
Takeda Pharmaceutical is a biopharmaceutical company.
Roche
Roche
Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
Bayer
Bayer
Bayer is a global life science company specializing in healthcare and nutrition.
Founding Date
Founding Date
1849
Founding Date
1991
Founding Date
1887
Founding Date
1876
Founding Date
2000
Founding Date
1886
Founding Date
1891
Founding Date
1996
Founding Date
1980
Founding Date
1781
Founding Date
1896
Founding Date
1863
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New York, US HQ
Melrose Park, AU
Wien, AT
Minsk, BY
Ixelles, BE
Sofia, BG
Kirkland, CA
see more
Locations
Lake Bluff, US HQ
Tiranë, AL
Buenos Aires, AR
Yerevan, AM
Doncaster, AU
Macquarie Park, AU
Melbourne, AU
see more
Locations
New York, US HQ
Braine L'alleud, BE
Montréal, CA
Montréal, CA
Pudong Xinqu, CN
Virum, DK
Espoo, FI
see more
Locations
Indianapolis, US HQ
Sydney, AU
Melrose Park, AU
Wien, AT
Charlottetown, CA
Toronto, CA
Baoding, CN
see more
Locations
Brentford, GB HQ
Tiranë, AL
Boudouaou, DZ
Victoria, AR
Abbotsford, AU
Boronia, AU
Wien, AT
see more
Locations
New Brunswick, US HQ
Buenos Aires, AR
Yerevan, AM
Ultimo, AU
Wien, AT
Minsk, BY
Beerse, BE
see more
Locations
Kenilworth, US HQ
Buenos Aires, AR
Adelaide, AU
Brisbane, AU
Canberra, AU
Perth, AU
Sydney, AU
see more
Locations
Basel, CH HQ
Tirana, AL
Bir Mourad Raïs, DZ
Duc, AR
Macquarie Park, AU
Wien, AT
Baku, AZ
see more
Locations
Thousand Oaks, US HQ
Hydra, DZ
Vicente López, AR
Kew, AU
North Ryde, AU
Wien, AT
Diegem, BE
see more
Locations
Chuo City, JP HQ
Sydney, AU
Linz, AT
Sint Jans Molenbeek, BE
Santo Amaro, BR
Oakville, CA
Shanghai, CN
see more
Locations
Basel, CH HQ
Hydra, DZ
Ricardo Rojas, AR
Bella Vista, AU
North Ryde, AU
Sydney, AU
Wien, AT
see more
Locations
Leverkusen, DE HQ
Luanda, AO
Munro, AR
Pymble, AU
Wien, AT
Dhaka, BD
Minsk, BY
see more
Employees
Employees
88,3004% decrease
Employees
107,0004% increase
Employees
30,00029% increase
Employees
33,62513% decrease
Employees
95,4903% decrease
Employees
132,2002% decrease
Employees
71,0003% increase
Employees
103,91417% decrease
Employees
23,4009% increase
Employees
49,57882% increase
Employees
94,4421% increase
Employees
103,8241% decrease
Valuation ($)
Valuation ($)
207.8 b
Valuation ($)
158.3 b
Valuation ($)
136.5 b
Valuation ($)
144.7 b
Valuation ($)
102.1 b
Valuation ($)
382 b
Valuation ($)
195 b
Valuation ($)
N/A
Valuation ($)
132.2 b
Valuation ($)
58.6 b
Valuation ($)
N/A
Valuation ($)
61.5 b
Twitter followers
Twitter followers
18.2 k
Twitter followers
101.7 k
Twitter followers
141.8 k
Twitter followers
69
Twitter followers
197.9 k
Twitter followers
196.7 k
Twitter followers
186.7 k
Twitter followers
268.7 k
Twitter followers
88.8 k
Twitter followers
N/A
Twitter followers
213.8 k
Twitter followers
173.2 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
3
Number of tweets (last 30 days)
297
Number of tweets (last 30 days)
55
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
81
Number of tweets (last 30 days)
96
Number of tweets (last 30 days)
53
Number of tweets (last 30 days)
31
Number of tweets (last 30 days)
75
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
98
Number of tweets (last 30 days)
58
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
12.3
Average likes per tweet (last 30 days)
14.3
Average likes per tweet (last 30 days)
19.5
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
24.2
Average likes per tweet (last 30 days)
15.2
Average likes per tweet (last 30 days)
25.5
Average likes per tweet (last 30 days)
14.3
Average likes per tweet (last 30 days)
25.3
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
33.6
Average likes per tweet (last 30 days)
24.6
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
51.85%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
82.72%
Percentage of tweets with engagement (last 30 days)
81.25%
Percentage of tweets with engagement (last 30 days)
98.11%
Percentage of tweets with engagement (last 30 days)
64.52%
Percentage of tweets with engagement (last 30 days)
97.33%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
98.98%
Percentage of tweets with engagement (last 30 days)
77.59%
Alexa Website Rank
Alexa Website Rank
33553
Alexa Website Rank
35563
Alexa Website Rank
133722
Alexa Website Rank
166332
Alexa Website Rank
55980
Alexa Website Rank
28232
Alexa Website Rank
100197
Alexa Website Rank
138421
Alexa Website Rank
165413
Alexa Website Rank
322730
Alexa Website Rank
91937
Alexa Website Rank
94682
Employee Rating
Employee Rating
4.0
Employee Rating
3.5
Employee Rating
3.9
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
4.0
Employee Rating
3.9
Employee Rating
3.9
Employee Rating
3.7
Employee Rating
N/A
Employee Rating
N/A
Employee Rating
N/A

Financial

Revenue (est.)
Revenue (est.)
$51.8b (FY, 2019)
Revenue (est.)
$31.9b (FY, 2019)
Revenue (est.)
$26.1b (FY, 2019)
Revenue (est.)
$22.3b (FY, 2019)
Revenue (est.)
£30.8b (FY, 2018)
Revenue (est.)
$82.1b (FY, 2019)
Revenue (est.)
$46.8b (FY, 2019)
Revenue (est.)
$49.1b (FY, 2017)
Revenue (est.)
$23.4b (FY, 2019)
Revenue (est.)
$1.8b (Y, 2015)
Revenue (est.)
CHF59.5b (FY, 2018)
Revenue (est.)
€43.5b (FY, 2019)
Cost of goods
Cost of goods
$10.2b (FY, 2019)
Cost of goods
$13.2b (FY, 2019)
Cost of goods
$8.1b (FY, 2019)
Cost of goods
$4.7b (FY, 2019)
Cost of goods
£10.2b (FY, 2018)
Cost of goods
$27.6b (FY, 2019)
Cost of goods
$14.1b (FY, 2019)
Cost of goods
$17.2b (FY, 2017)
Cost of goods
$4.4b (FY, 2019)
Cost of goods
N/A
Cost of goods
CHF17.3b (FY, 2018)
Cost of goods
€17.5b (FY, 2019)
Gross profit
Gross profit
$41.5b (FY, 2019)
Gross profit
$18.7b (FY, 2019)
Gross profit
$18.1b (FY, 2019)
Gross profit
$17.6b (FY, 2019)
Gross profit
£20.6b (FY, 2018)
Gross profit
$54.5b (FY, 2019)
Gross profit
$32.7b (FY, 2019)
Gross profit
$31.9b (FY, 2017)
Gross profit
$19b (FY, 2019)
Gross profit
N/A
Gross profit
CHF42.2b (FY, 2018)
Gross profit
€26.1b (FY, 2019)
Net income
Net income
$16.3b (FY, 2019)
Net income
$3.7b (FY, 2019)
Net income
$3.4b (FY, 2019)
Net income
$8.3b (FY, 2019)
Net income
£4b (FY, 2018)
Net income
$15.1b (FY, 2019)
Net income
$9.8b (FY, 2019)
Net income
$7.7b (FY, 2017)
Net income
$7.8b (FY, 2019)
Net income
$83.5 (Y, 2015)
Net income
CHF10.9b (FY, 2018)
Net income
€2.4b (FY, 2019)

Operating

Countries
Countries
125 (FY, 2017)
Countries
N/A
Countries
N/A
Countries
N/A
Countries
100 (FY, 2018)
Countries
60 (FY, 2018)
Countries
N/A
Countries
N/A
Countries
100 (FY, 2019)
Countries
N/A
Countries
N/A
Countries
153 (FY, 2018)
Manufacturing Facilities
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
87 (FY, 2016)
Manufacturing Facilities
97 (FY, 2019)
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Facilities
N/A
Manufacturing Sites
Manufacturing Sites
58 (FY, 2017)
Manufacturing Sites
92 (FY, 2019)
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
N/A
Manufacturing Sites
26 (FY, 2018)
Manufacturing Sites
N/A
New Product Launches
New Product Launches
N/A
New Product Launches
25 (FY, 2018)
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
30 (FY, 2016)
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
New Product Launches
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
19 (Apr, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2019)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
12 (Jan, 2020)
Phase III Trials Products
Phase III Trials Products
29 (FY, 2017)
Phase III Trials Products
N/A
Phase III Trials Products
8 (FY, 2016)
Phase III Trials Products
19 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
24 (Apr, 2020)
Phase III Trials Products
37 (FY, 2017)
Phase III Trials Products
14 (Feb, 2020)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
9 (Jan, 2020)
Products
Products
N/A
Products
1.5 k (FY, 2018)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
98 (Apr, 2020)
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Products
N/A
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
44 (FY, 2016)
Projects in R&D Pipeline
66 (FY, 2016)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
10 (May, 2018)
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Research and Development Centers
Research and Development Centers
N/A
Research and Development Centers
12 (FY, 2017)
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
N/A
Research and Development Centers
30 (FY, 2018)
Research and Development Centers
N/A
Suppliers
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
3.5 k (Jun, 2018)
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
N/A
Suppliers
86.4 k (FY, 2019)
US FDA Breakthrough Therapy Designations
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
6 (FY, 2017)
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
N/A
US FDA Breakthrough Therapy Designations
6 (FY, 2018)
US FDA Breakthrough Therapy Designations
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 6.9m
Total funding raised
$ 15.5m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 5m
Total funding raised
$ 6.5m
Total funding raised
$ 175.5m
Total funding raised
$ 57.8m
Total funding raised
$ 2.8b
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Abbott
HQ
Lake Bluff, US
Employees
107,000↑ 4% increase

Abbott is a healthcare company specializing in diagnostics, medical devices, nutritionals, and branded generic medicines.

View company
Bristol-Myers Squibb
HQ
New York, US
Employees
30,000↑ 29% increase

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases.

View company
Eli Lilly
HQ
Indianapolis, US
Employees
33,625↓ 13% decrease

Eli Lilly and Company is engaged in the discovery, development, manufacture, and sale of products in the pharmaceutical business segment.

View company
GlaxoSmithKline
HQ
Brentford, GB
Employees
95,490↓ 3% decrease

GlaxoSmithKline is a science-led healthcare company.

View company